JPMorgan Day 3: Bluebird Bio preps for beti-cel launch
Bluebird Bio's beta thalassemia gene therapy already under review in Europe - STAT
Bluebird Bio Eliminating 30% of Workforce in Restructuring
bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference | Business Wire
bluebird bio (@bluebirdbio) / Twitter
Bluebird Bio Says Cash Crunch Raises 'Going Concern' Risk - Bloomberg
bluebird bio: Potential For 3 Gene Therapy Approvals (NASDAQ:BLUE) | Seeking Alpha
bluebird bio (@bluebirdbio) / Twitter
Low on cash, Bluebird Bio and its gene therapies face uncertain future
Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany
bluebird bio submits BLA for single-dose gene therapy to treat beta-thalassemia
bluebird bio completes spin-off of cell therapy company 2seventy bio | Seeking Alpha
Bluebird Bio gene therapy wins first FDA approval for rare blood disorder - MedCity News
Why Bluebird Bio (BLUE) Stock Is Getting Hammered | Markets Insider
bluebird bio | Pioneering Gene Therapies | Recode for Life
bluebird bio plans 'new nest' around hybrid work model
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions | Business
Bluebird Bio CEO on new study data: We're getting profound responses
Articles with bluebird bio
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
BlueBird Bio's 2-day reckoning is at hand - News - MM+M
Bluebird Bio's Rare Disease Gene Therapies Recommended for FDA Approval
Nick Leschly, CEO of bluebird bio spinout 2seventy bio says 2023 will be a 'special year' - Boston Business Journal
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies – TIF
Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license - Boston Business Journal
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies | Business Wire
ICER says bluebird bio's $2.1m gene therapy is cost-effective | pharmaphorum
